FR22C1005I1 - Nouveaux agonistes des recepteurs adrenergiques alpha2 - Google Patents
Nouveaux agonistes des recepteurs adrenergiques alpha2Info
- Publication number
- FR22C1005I1 FR22C1005I1 FR22C1005C FR22C1005C FR22C1005I1 FR 22C1005 I1 FR22C1005 I1 FR 22C1005I1 FR 22C1005 C FR22C1005 C FR 22C1005C FR 22C1005 C FR22C1005 C FR 22C1005C FR 22C1005 I1 FR22C1005 I1 FR 22C1005I1
- Authority
- FR
- France
- Prior art keywords
- new
- receptor agonists
- adrenergic receptor
- alpha2 adrenergic
- alpha2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619109P | 2012-04-02 | 2012-04-02 | |
| PCT/FI2013/000013 WO2013150173A1 (fr) | 2012-04-02 | 2013-03-28 | Nouveaux agonistes du récepteur adrénergique alpha2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR22C1005I1 true FR22C1005I1 (fr) | 2022-03-11 |
Family
ID=48224812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR22C1005C Active FR22C1005I1 (fr) | 2012-04-02 | 2022-01-31 | Nouveaux agonistes des recepteurs adrenergiques alpha2 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9249127B2 (fr) |
| EP (1) | EP2834233B1 (fr) |
| JP (1) | JP6427096B2 (fr) |
| KR (1) | KR102104228B1 (fr) |
| CN (1) | CN104220437B (fr) |
| AR (1) | AR090557A1 (fr) |
| AU (1) | AU2013244859B2 (fr) |
| BR (1) | BR112014023957B1 (fr) |
| CA (1) | CA2868611C (fr) |
| DK (1) | DK2834233T3 (fr) |
| ES (1) | ES2674945T3 (fr) |
| FR (1) | FR22C1005I1 (fr) |
| HK (1) | HK1205115A1 (fr) |
| HR (1) | HRP20181203T1 (fr) |
| HU (2) | HUE039290T2 (fr) |
| IL (1) | IL234663B (fr) |
| LT (2) | LT2834233T (fr) |
| MX (1) | MX358429B (fr) |
| NL (1) | NL301160I2 (fr) |
| NO (1) | NO2022002I1 (fr) |
| PL (1) | PL2834233T3 (fr) |
| PT (1) | PT2834233T (fr) |
| RU (1) | RU2642065C2 (fr) |
| SI (1) | SI2834233T1 (fr) |
| TW (1) | TWI620746B (fr) |
| WO (1) | WO2013150173A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015152196A1 (ja) * | 2014-03-31 | 2017-04-13 | 東レ株式会社 | イミダゾリン誘導体及びその医薬用途 |
| EP3256466B9 (fr) * | 2015-02-11 | 2022-07-27 | Sunovion Pharmaceuticals Inc. | Composes 1-hétérocycyl-isochromane et analogues correspondants pour le traitement de troubles du snc |
| CN105646306B (zh) * | 2015-12-11 | 2020-06-30 | 广东莱佛士制药技术有限公司 | 一种4-甲硫基苯乙酸的制备方法 |
| SI3717476T1 (sl) | 2017-12-01 | 2022-10-28 | Orion Corporation | Postopek priprave 2-(5-metoksiizokroman-1-il)-4,5-dihidro-1H-imidazola in njegove hidrogensulfatne soli |
| CN110272407B (zh) * | 2019-07-22 | 2021-02-05 | 河北省农林科学院经济作物研究所 | 一种用于降血压的天然异色满酮类化合物 |
| CN117157070A (zh) | 2021-03-19 | 2023-12-01 | 奥赖恩公司 | 他西匹啶(tasipimidine)制剂及其用途 |
| WO2023139313A1 (fr) | 2022-01-24 | 2023-07-27 | Orion Corporation | Nouvelles formes de sel de sulfate d'agoniste d'adrénorécepteur alpha-2 à structure isochroman-imidazole |
| WO2023148431A1 (fr) | 2022-02-04 | 2023-08-10 | Orion Corporation | Nouvelles formes de sel d'un agoniste de l'adrénorécepteur alpha-2a à structure isochroman-imidazole |
| WO2024069050A1 (fr) | 2022-09-28 | 2024-04-04 | Orion Corporation | Polythérapie à base de tasipimidine et d'inhibiteur de cyp2d6 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1247008B (de) * | 1965-10-05 | 1967-08-10 | Huels Chemische Werke Ag | Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen |
| US3438995A (en) * | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| DE3583900D1 (de) * | 1984-06-06 | 1991-10-02 | Abbott Lab | Adrenergische verbindungen. |
| EP1413576A3 (fr) * | 1997-12-04 | 2004-09-01 | Allergan, Inc. | Dérivés d'imidazoles substituées et leur utilisation en tant qu'agonistes des récepteurs adrénergiques alpha 2B ou 2B/2C |
| FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| AU2007209382A1 (en) | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of CNS disorders |
| JP2009524616A (ja) | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ疾患のための４−イミダゾール誘導体の使用 |
| US20080020076A1 (en) * | 2006-07-21 | 2008-01-24 | Khem Jhamandas | Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists |
-
2013
- 2013-03-27 AR ARP130101043 patent/AR090557A1/es active IP Right Grant
- 2013-03-28 EP EP13719297.7A patent/EP2834233B1/fr active Active
- 2013-03-28 ES ES13719297.7T patent/ES2674945T3/es active Active
- 2013-03-28 WO PCT/FI2013/000013 patent/WO2013150173A1/fr active Application Filing
- 2013-03-28 AU AU2013244859A patent/AU2013244859B2/en active Active
- 2013-03-28 BR BR112014023957-6A patent/BR112014023957B1/pt active IP Right Grant
- 2013-03-28 PT PT137192977T patent/PT2834233T/pt unknown
- 2013-03-28 PL PL13719297T patent/PL2834233T3/pl unknown
- 2013-03-28 CN CN201380018776.XA patent/CN104220437B/zh active Active
- 2013-03-28 CA CA2868611A patent/CA2868611C/fr active Active
- 2013-03-28 JP JP2015503903A patent/JP6427096B2/ja active Active
- 2013-03-28 KR KR1020147027610A patent/KR102104228B1/ko active IP Right Grant
- 2013-03-28 HU HUE13719297A patent/HUE039290T2/hu unknown
- 2013-03-28 SI SI201331024T patent/SI2834233T1/en unknown
- 2013-03-28 MX MX2014011851A patent/MX358429B/es active IP Right Grant
- 2013-03-28 US US14/389,466 patent/US9249127B2/en active Active
- 2013-03-28 DK DK13719297.7T patent/DK2834233T3/en active
- 2013-03-28 LT LTEP13719297.7T patent/LT2834233T/lt unknown
- 2013-03-28 RU RU2014144284A patent/RU2642065C2/ru active
- 2013-03-29 TW TW102111298A patent/TWI620746B/zh active
-
2014
- 2014-09-15 IL IL234663A patent/IL234663B/en active IP Right Grant
-
2015
- 2015-06-16 HK HK15105661.0A patent/HK1205115A1/xx unknown
-
2018
- 2018-07-25 HR HRP20181203TT patent/HRP20181203T1/hr unknown
-
2022
- 2022-01-27 NO NO2022002C patent/NO2022002I1/no unknown
- 2022-01-31 NL NL301160C patent/NL301160I2/nl unknown
- 2022-01-31 FR FR22C1005C patent/FR22C1005I1/fr active Active
- 2022-02-02 HU HUS2200005C patent/HUS2200005I1/hu unknown
- 2022-02-03 LT LTPA2022001C patent/LTPA2022001I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1005I1 (fr) | Nouveaux agonistes des recepteurs adrenergiques alpha2 | |
| CO6862160A2 (es) | Indazoles | |
| CO6811864A2 (es) | Piridin-2-amidas útiles como agonistas de cb2 | |
| DE102013109517A8 (de) | Antivibrationsklemme | |
| UA26820S (uk) | Телефон головний | |
| DK2776436T3 (da) | Nye forbindelser | |
| ES2643056T3 (es) | Piridina-2-amidas útiles como agonistas de cb2 | |
| DK2928870T3 (da) | Neurotensin-receptorligander | |
| DK3312169T3 (da) | 5-ht3 receptorantagonister | |
| DK2758523T3 (da) | Stromastamceller | |
| CO6970588A2 (es) | Ligandos del receptor ep1 | |
| DK2671011T3 (da) | Klemring | |
| BR112013019514A2 (pt) | celobiohidrolase mutante | |
| BR112014032413A2 (pt) | tanque | |
| DK3106464T3 (da) | Nye forbindelser | |
| DE112012005400A5 (de) | Sattel | |
| BR112013032213A2 (pt) | cocho independente | |
| BR112014004742A2 (pt) | calheira | |
| CO6920305A2 (es) | Heterociclilpiri(mi)dinilpirazol | |
| DK2877173T3 (da) | Antagonister / inverse agonister til cannabinoidreceptorer | |
| FR2985656B1 (fr) | Oxymetre | |
| CO6920302A2 (es) | Heterociclilpir(mi)dinilpirazoles | |
| DK2849764T3 (da) | Sporstofopløsning | |
| DE102011106569A8 (de) | Haltevorrichtung | |
| TH1401000932B (th) | ตัวจับยึดท่อ |